A deep belief network-based method to identify proteomic risk markers
  for Alzheimer disease
  While a large body of research has formally identified apolipoprotein E
(APOE) as a major genetic risk marker for Alzheimer disease, accumulating
evidence supports the notion that other risk markers may exist. The traditional
Alzheimer-specific signature analysis methods, however, have not been able to
make full use of rich protein expression data, especially the interaction
between attributes. This paper develops a novel feature selection method to
identify pathogenic factors of Alzheimer disease using the proteomic and
clinical data. This approach has taken the weights of network nodes as the
importance order of signaling protein expression values. After generating and
evaluating the candidate subset, the method helps to select an optimal subset
of proteins that achieved an accuracy greater than 90%, which is superior to
traditional machine learning methods for clinical Alzheimer disease diagnosis.
Besides identifying a proteomic risk marker and further reinforce the link
between metabolic risk factors and Alzheimer disease, this paper also suggests
that apidonectin-linked pathways are a possible therapeutic drug target.
